For US Healthcare Professionals Only
Filter
35 result(s)
Filter
*Includes seizure clusters and acute or prolonged seizures
255 result(s)
“How quickly will I feel better with this new drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
A Novel International Patient Registry in Myasthenia Gravis Linking Clinical and Patient-Reported Outcomes Data: The Vitaccess Real MG (VRMG) Registry
A Post-Hoc Evaluation of Fenfluramine With or Without Vagus Nerve Stimulation in Lennox-Gastaut Syndrome Clinical Trials
A retrospective claims study evaluating mortality in patients with Lennox-Gastaut or Dravet syndrome in the United States
A Stratified Analysis of Efficacy and Safety of Fenfluramine in Patients With Dravet Syndrome
A stratified analysis of efficacy and safety of fenfluramine in patients with Dravet syndrome
Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS Inactive Disease in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Trials
Achieving Greater Disease Control Criteria was Associated with Improved Work Productivity in Patients with Psoriatic Arthritis up to 2 Years
Analysis of Safety, Tolerability and Clinical Global Impression-Improvement Scale Ratings in Patients With Dravet Syndrome Enrolled as Adults in a Fenfluramine Open-Label Extension Study
Antiseizure Medication Regimen Adjustment After Fenfluramine Initiation: Lessons Learned From European Early Access Program in Pediatric and Adult Patients With Dravet Syndrome
Automated assessment of sleep in healthy pediatrics from simulated behind-the-ear EEG
Automated Assessment of Sleep in Patients With Dravet Syndrome From Simulated Behind-the-Ear EEG
Barriers and Facilitators to Quality HS Biologic Care and Outcomes for the Medicaid Population Across US States
Bimekizumab 2-year Efficacy by Prior Biologic Use in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 2-Year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Bimekizumab 2-year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 2-year Maintenance of Response in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT
Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Bimekizumab 5-year maintenance of response in US and Canadian patients with psoriasis who responded at Week 16
Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Bimekizumab cumulative health-related quality of life benefit by clinical response in patients with hidradenitis suppurativa: 1 year data from BE HEARD I&II
Bimekizumab Demonstrated Similar Efficacy and Safety in Two Clinical Endotypes of Axial Spondyloarthritis: 1-Year Results from Two Phase 3 Trials
Bimekizumab Demonstrated Sustained Efficacy and Safety Across the Full Spectrum of Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Bimekizumab Demonstrates Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab effect on pain severity and impact in moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bimekizumab Efficacy Across Subgroups of Patients With Moderate to Severe Plaque Psoriasis: Pooled Analysis From up to 3 Years of Treatment in 5 Phase 3/3b Clinical Trials
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-term Results from a Phase 3 Study and Open-Label Extension
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Bimekizumab efficacy in patients with plaque psoriasis: A post hoc stratification by weight over 4 years in BE BRIGHT
Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT
Bimekizumab impact on clinical markers of liver fibrosis and key liver parameters in patients with moderate to severe plaque psoriasis: Long-term pooled data from BE BRIGHT
Bimekizumab impact on draining tunnel and lesion count over 2 years in hidradenitis suppurativa: Data from BE HEARD EXT
Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT
Bimekizumab Impact on Draining Tunnels Over 2 Years in HS: Data from BE HEARD EXT
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on efficacy and patient-reported outcomes in moderate versus severe hidradenitis suppurativa
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab in routine clinical practice: Baseline characteristics and treatment history of patients with moderate to severe plaque psoriasis from the second interim analysis of ELEVATE
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Bimekizumab Maintained Efficacy Responses in Patients With Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab maintenance of efficacy over 4 years in biologic-naïve andbiologic-experienced patients with moderate to severe plaque psoriasis
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Bimekizumab maintenance of response during treatment interruption and retreatment in US/Canadian patients with psoriasis
Bimekizumab maintenance of response from the end of pivotal trials through 4 years: Results in patients with moderate to severe plaque psoriasis from BE BRIGHT
Bimekizumab PASI response levels in Week 16 PASI responders with moderate to severe plaque psoriasis through 4 years: Results from BE BRIGHT
Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicenter, randomized, open-label studies
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicentre, randomised, open-label studies
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Bimekizumab time to onset of PASI response in patients with psoriasis in three head-to-head phase 3/3b studies
Bimekizumab treatment history and clinical outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Bimekizumab treatment history and quality of life outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Bimekizumab treatment in plaque psoriasis resulted in a rapid and deep normalisation of molecular signatures associated with PASI sub-components, that preceded clinical skin clearance
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two phase 3 studies
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 2-year results from two phase 3 studies
Bimekizumab Treatment was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab, a Dual Inhibitor of IL-17A and IL-17F, Demonstrated Long-Term Safety and Efficacy in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: Final 3-Year Results from the Phase 3 BE OPTIMAL Study and its Open-Label Extension
Bimekizumab: Exploring the fast onset, high level, and durability of clinical and molecular responses in patients with psoriatic disease – Design and rationale behind the exploratory, multicentre, open-label phase 3b BE UNIQUE study
Bimekizumab: Network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients
Brivaracetam adjunctive therapy in earlier treatment lines in adults with focal-onset seizures in Europe and Canada: second interim results of 12-month real-world data from BRITOBA
Brivaracetam monotherapy patient characteristics, treatment patterns, and healthcare resource utilization among patients with epilepsy: a cohort study using US claims data
Burden and impact of caring for those with thymidine kinase 2 deficiency (TK2d): results from the Assessment of TK2d Patient Perspectives (ATP) study
Caregiver Versus Investigator Clinical Global Impression-Improvement Ratings in Fenfluramine Clinical Trials
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Comparative Effectiveness of Fenfluramine Versus Cannabidiol in Dravet Syndrome: A Numbers Needed to Treat Indirect Comparison Analysis
Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: A post hoc analysis of the RAISE-XT study
Comprehensive Analysis of Lennox-Gastaut Syndrome in Europe: Treatment Patterns, Healthcare Utilisation, and Quality of Life
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Correlation between MG Symptoms PRO and existing MG‑specific outcome scores in the Phase 3 MycarinG study: Post hoc analysis
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Developing needs-driven medical education for healthcare professionals in myasthenia gravis
Development and validation of a claims-based algorithm for hidradenitis suppurativa severity
Development of an Electronic Decision-Assisting Tool for the Evaluation of the Likelihood of Lennox-Gastaut Syndrome (LGS) Diagnosis
Disruptive impacts of developmental and epileptic encephalopathies on patient and family life: a quality-of-life survey
Disruptive Impacts of Developmental and Epileptic Encephalopathies on Patient and Family Life: A Quality-of-Life Survey
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Dual Inhibition of IL-17A and IL-17F with Bimekizumab Demonstrated Long-Term Safety and Efficacy in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors
Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: Post hoc item-level analysis of MycarinG
Effect of rozanolixizumab on myasthenia gravis-specific outcome subdomain scores: Post hoc analyses from the Phase 3 MycarinG study
Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-specific outcomes in MycarinG
Effect of zilucoplan on myasthenia gravis-specific outcome subdomain scores in RAISE: A Phase 3 study
Effectiveness and Tolerability of Adjunctive Brivaracetam in Adults With Focal-Onset Seizures on One Specific Antiseizure Medication: Post Hoc Analysis of Interim Real‐World Data From BRITOBA
Effectiveness and Tolerability of Brivaracetam in Adults With Epilepsy Etiology of Cerebral Neoplasm, Cerebrovascular Accident, or Cranial Trauma: Pooled Data Analyses From Two Real-World Studies
Efficacy and safety of bimekizumab to 2 years in patients with psoriatic arthritis by baseline psoriasis severity
Efficacy of zilucoplan in patients with generalized myasthenia gravis without prior immunoglobulin or plasma exchange in the RAISE study
Evaluating mental health in caregivers of patients with Dravet syndrome: a systematic review
Evidence of misdiagnosis in administrative claims data for individuals with myasthenia gravis
Experiences of women of childbearing age with epilepsy throughout their motherhood journey: results from a social media listening study
Expert Consensus Recommendations on Seizure Emergencies Suitable for Rapid and Early Seizure Termination (REST) and Timing of Intervention
Fenfluramine Efficacy Trajectories in Placebo or Treatment Groups From Randomized Controlled Trial to Open-Label Extension
Fenfluramine Increases Seizure-Free Days in Patients With Lennox-Gastaut Syndrome
Fenfluramine Safety: An Update From Post-Marketing Reports
Fragment Crystallizable (Fc)-Free Certolizumab Pegol is not Bound by Rheumatoid Factors, while Fc Containing Biological DMARDs Are, Driving Immune Complex Formation and Cellular Clearance
Functional outcomes in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy
Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomized, parallel-group study
HEADFIRST: Preliminary Results From Home Sleep EEG Testing in Patients With LGS
Healthcare Utilization and Persistence in Patients With Dravet Syndrome: A Retrospective Analysis Using US Claims Data
IL-17 Unmasked: Unraveling the Story of Inflammation in SpA Symposium Recording
Impact of fenfluramine on convulsive seizure frequency in dose-capped patients with Dravet syndrome
Impact of prolonged seizures on patients’ and caregivers’ quality of life
Impact of Prolonged Seizures on Patients’ and Caregivers’ Quality of Life
Inhalation as an Efficient Delivery Route of Alprazolam for the Treatment of Acute Seizures: Randomized Study of Staccato®Alprazolam Relative to Oral Alprazolam
Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and Its Open-Label Extension
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Insights into Lennox-Gastaut Syndrome: A European Real-World Study on Patient Profiles and Unmet Needs
Interim Results of the US Fenfluramine Oral Solution Cardiovascular Safety Registry Study
Interim results of the US fenfluramine oral solution cardiovascular safety registry study
Long-Term Efficacy and Tolerability of Brivaracetam in Pediatric Patients With Focal-Onset Seizures and Cognitive or Learning Comorbidities: Post Hoc Analysis of an Open-Label Trial
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Updated results from phase 2b/3 studies and their open-label extensions
Long-term safety outcomes of rozanolixizumab treatment in patients with generalized myasthenia gravis: A pooled analysis
Long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies
Long-Term Tolerability and Efficacy of Adjunctive Brivaracetam in Pediatric Patients With Primary Generalized Seizures: Subgroup Analysis of an Open-Label, Follow-Up Trial
Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with primary generalized seizures: subgroup analysis of an open-label, follow-up trial
Long-term zilucoplan in generalized myasthenia gravis: 96-week follow-up interim analysis of RAISE-XT
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Maintenance of stringent clinical responses with bimekizumab in patients with axial spondyloarthritis: 2-year outcomes from two phase 3 studies
Markers of IL-17 Signalling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumour Necrosis Factor Inhibitors
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 years of Bimekizumab Treatment: Results from a Phase 3 Open-label Extension Study
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis Over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
Minimal symptom expression in generalized myasthenia gravis: A post hoc analysis of MycarinG and open-label studies
Modeling Systemic Exposure to Fenfluramine and its Active Metabolite, Norfenfluramine, in Patients With Dravet Syndrome
Non-steroidal immunosuppressant therapy changes during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Ocular symptoms in patients with generalized myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Onset and Duration of Adverse Events in Patients Treated With Fenfluramine in the Lennox-Gastaut Syndrome Clinical Trials
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization Among Patients With Epilepsy on Brivaracetam Monotherapy: A Cohort Study Using US Claims Data
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Patient experiences of thymidine kinase 2 deficiency (TK2d): preliminary results from an online survey conducted in partnership with the patient community
Patient-Reported Outcomes in Adults With Focal-Onset Seizures Who Completed 12 Months of Adjunctive Brivaracetam in Earlier Treatment Lines: Post Hoc Analysis of Interim Real-World Data From BRITOBA
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Patients’ lived experience of thymidine kinase 2 deficiency (TK2d): results from the Assessment of TK2d Patient Perspectives (ATP) study
Pharmacokinetics of Fenfluramine and its Active Metabolite Norfenfluramine in Patients with Lennox-Gastaut Syndrome
Point-Counterpoint: An Expert-led Discussion on Generalized Myasthenia Gravis (gMG) Treatment Choice
Post-Hoc Analysis of Fenfluramine for Lennox-Gastaut Syndrome by Baseline Frequency Quartiles of Seizures Associated With a Fall
Preliminary baseline results from the CANDID study: An observational study in patients with CDKL5 Deficiency Disorder
Pulmonary safety of Staccato®alprazolam in healthy participants and participants with mild asthma: phase 1, randomised, double-blind, placebo-controlled trial
Rapid joint and skin responses were observed in patients with active psoriatic arthritis treated with bimekizumab: A pooled analysis from two phase 3 studies
Rare Disease Connect in Neurology (RDCN): An international MG community and forum providing needs-driven medical education
Real world use of fenfluramine for Dravet syndrome: a retrospective cohort study using a national pharmacy database
Real-World Use of Fenfluramine for Dravet Syndrome: A Retrospective Cohort Study Using a National Pharmacy Database
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Response over time with zilucoplan in generalized myasthenia gravis: Post hoc analysis of RAISE-XT 60-week follow up
Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT
Response rates with zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis
Safety and Effectiveness of Adjunctive Fenfluramine in an Open-Label Extension Study of Children (Under 6 Years Old) With Dravet Syndrome
Safety and effectiveness of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: results from the final analysis of an open-label extension study
Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)
Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalized myasthenia gravis (MG0004)
Safety, tolerability, pharmacokinetics, and efficacy of fenfluramine in combination with cannabidiol: results from an exploratory phase 1 study
Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Sleep Apnea is Associated With High Mortality Risk in Children With Severe Epilepsies: An Observational Analysis From Large Scale US Claims Data
Sleep Apnea is Associated With High Mortality Risk in Children With Severe Epilepsies: An Observational Analysis From Large Scale US Claims Data
Social determinants of health are associated with delayed diagnosis in myasthenia gravis
Solutions to address the unmet needs of the gMG patient journey in the US: A multistakeholder Delphi consensus study
Subcutaneous Infusions in Generalized Myasthenia Gravis: Understanding the Administration of Rozanolixizumab-noli
Survival analyses in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy
Survival and functional outcomes in patients with thymidine kinase 2 deficiency aged >12 years at symptom onset who received pyrimidine nucleos(t)ides
Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Sustained Symptom Improvement in Psoriatic Arthritis with 2-Year Bimekizumab Treatment Based on Routine Assessment of Patient Index Data 3
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study
Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study
The Diagnostic Dilemma: Genetic Testing vs. Muscle Biopsy in Mitochondrial Myopathies
The disease course of untreated patients with thymidine kinase 2 deficiency (TK2d) aged >12 years at TK2d symptom onset: findings from the largest international TK2d dataset
The disease course of untreated patients with thymidine kinase 2 deficiency (TK2d) aged ≤12 years at TK2d symptom onset: findings from the largest international TK2d dataset
Time Course of Treatment-Emergent Adverse Events in Adult Asian Patients With Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: A Post Hoc Analysis of a Phase III, Randomized Trial
Tolerability and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients With Focal-Onset Seizures: Interim and Post Hoc Analysis of a Phase 3, Open-Label Extension Trial
Treatment satisfaction, work productivity, and quality of life under adjunctive brivaracetam in earlier treatment lines in adults with focal-onset seizures: 12-month real-world data from BRITOBA
Understanding the incidence, prevalence, characteristics, and healthcare resource utilization for patients with Dravet and Lennox-Gastaut syndromes
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Using the Genomics England National Genomic Research Library (NGRL) and UK Biobank to investigate the genetic, phenotypic and clinical landscape of thymidine kinase 2 deficiency (TK2d)
What Are the Experiences of Women of Childbearing Age With Epilepsy Throughout Their Motherhood Journey? Results From a Social Media Listening Study